{"hands_on_practices": [{"introduction": "Before embarking on the complex task of engineering a metabolic pathway, a crucial first step is to determine its theoretical potential. By applying the principle of mass conservation, we can calculate the maximum theoretical yield, which represents the upper limit of efficiency for converting a substrate into a product. This foundational calculation [@problem_id:2057427] provides a vital benchmark against which to measure the performance of our engineered strain and helps to assess the economic viability of a bioprocess from the outset.", "problem": "In a synthetic biology project, a research team is engineering a microbial strain to produce a valuable aromatic compound from a simple sugar. The engineered pathway uses glucose ($\\text{C}_6\\text{H}_{12}\\text{O}_6$) as the sole carbon source and converts it into a target compound with the chemical formula $\\text{C}_8\\text{H}_{10}\\text{O}_2$. The goal is to determine the theoretical upper limit for the efficiency of this bioconversion process.\n\nAssuming that the conversion pathway is optimized such that all carbon atoms from the consumed glucose are incorporated into the final product (i.e., there is no loss of carbon to byproducts like $\\text{CO}_2$ or to biomass formation), calculate the maximum theoretical carbon yield.\n\nFor your calculations, use the following atomic masses:\n- Carbon (C): 12.01 g/mol\n- Hydrogen (H): 1.008 g/mol\n- Oxygen (O): 16.00 g/mol\n\nExpress your answer as the mass of the target compound produced in grams per gram of glucose consumed. Round your final numerical answer to three significant figures.", "solution": "Define $n_{g}$ as the moles of glucose $\\text{C}_{6}\\text{H}_{12}\\text{O}_{6}$ consumed and $n_{p}$ as the moles of product $\\text{C}_{8}\\text{H}_{10}\\text{O}_{2}$ formed. With all carbon from glucose incorporated into product and no carbon losses, the carbon balance is\n$$6\\,n_{g} = 8\\,n_{p} \\quad \\Rightarrow \\quad \\frac{n_{p}}{n_{g}} = \\frac{6}{8} = \\frac{3}{4}.$$\nThe mass yield in grams of product per gram of glucose is\n$$Y = \\frac{m_{p}}{m_{g}} = \\frac{n_{p} M_{p}}{n_{g} M_{g}} = \\frac{3}{4}\\,\\frac{M_{p}}{M_{g}},$$\nwhere $M_{g}$ and $M_{p}$ are the molar masses of glucose and the product, respectively.\n\nUsing the given atomic masses, compute\n$$M_{g} = 6(12.01) + 12(1.008) + 6(16.00) = 72.06 + 12.096 + 96.00 = 180.156 \\text{ g/mol},$$\n$$M_{p} = 8(12.01) + 10(1.008) + 2(16.00) = 96.08 + 10.08 + 32.00 = 138.16 \\text{ g/mol}.$$\nTherefore,\n$$Y = \\frac{3}{4}\\,\\frac{138.16}{180.156} = \\frac{103.62}{180.156} \\approx 0.575168\\ldots$$\nRounded to three significant figures, the maximum theoretical carbon yield is $0.575$ grams of product per gram of glucose.", "answer": "$$\\boxed{0.575}$$", "id": "2057427"}, {"introduction": "While stoichiometry defines the theoretical limits of production, the actual performance of a synthetic pathway is governed by its reaction dynamics. The kinetic properties of each enzyme play a critical role in controlling the flow of metabolites, or flux, through the pathway. This conceptual problem [@problem_id:2057431] explores how a single, highly efficient enzyme can dramatically influence the concentration of pathway intermediates, a key factor in avoiding metabolic bottlenecks and the accumulation of potentially toxic compounds.", "problem": "A team of synthetic biologists is engineering *Escherichia coli* to produce a valuable pharmaceutical precursor, compound P. They have designed a novel three-enzyme linear pathway: $S \\xrightarrow{E_1} I_1 \\xrightarrow{E_2} I_2 \\xrightarrow{E_3} P$. In this pathway, an abundant cellular substrate $S$ is converted by enzyme $E_1$ into intermediate $I_1$. Intermediate $I_1$ is then the substrate for enzyme $E_2$, which converts it to $I_2$. Finally, enzyme $E_3$ converts $I_2$ into the desired product $P$.\n\nThe initial substrate, $S$, is supplied continuously to the cells and its concentration can be considered constant and non-limiting. Kinetic analysis of the purified enzymes reveals that $E_1$ and $E_3$ have moderate catalytic efficiencies. In contrast, enzyme $E_2$ has been specifically optimized and exhibits an exceptionally low Michaelis constant ($K_M$) for its substrate $I_1$ and a very high turnover number ($k_{cat}$).\n\nAssuming the pathway reaches a steady state where the rate of production of each intermediate equals its rate of consumption, what is the most likely consequence of $E_2$'s specific kinetic properties on the intracellular concentration of the intermediate $I_1$?\n\nA. The concentration of $I_1$ will be maintained at a very low level.\n\nB. The concentration of $I_1$ will build up to a very high level.\n\nC. The concentration of $I_1$ will be approximately equal to the $K_M$ value of enzyme $E_1$.\n\nD. The concentration of $I_1$ will be approximately equal to the $K_M$ value of enzyme $E_2$.\n\nE. The concentration of $I_1$ will undergo sustained oscillations.", "solution": "Let the pathway be $S \\xrightarrow{E_{1}} I_{1} \\xrightarrow{E_{2}} I_{2} \\xrightarrow{E_{3}} P$ with steady-state flux $v$ such that the production and consumption rates of each intermediate are equal. Under Michaelisâ€“Menten kinetics for each step, define $V_{\\max,i} = k_{cat,i} E_{i,\\text{tot}}$ and $K_{M,i}$ as the Michaelis constant for the substrate of $E_{i}$.\n\nBecause $S$ is abundant and effectively constant, the rate of the first step is\n$$\nv_{1} = \\frac{V_{\\max,1}[S]}{K_{M,1} + [S]}.\n$$\nThe rate of the second step consuming $I_{1}$ is\n$$\nv_{2} = \\frac{V_{\\max,2}[I_{1}]}{K_{M,2} + [I_{1}]}.\n$$\nThe third step is\n$$\nv_{3} = \\frac{V_{\\max,3}[I_{2}]}{K_{M,3} + [I_{2}]}.\n$$\n\nAt steady state, the fluxes are equal:\n$$\nv \\equiv v_{1} = v_{2} = v_{3}.\n$$\nThe intracellular concentration $[I_{1}]$ is determined by balancing its production and consumption, i.e., $v_{1} = v_{2}$. Setting $v_{1} = v_{2}$ and solving for $[I_{1}]$ gives\n$$\nv_{1} = \\frac{V_{\\max,2}[I_{1}]}{K_{M,2} + [I_{1}]}\n\\quad \\Longrightarrow \\quad\nv_{1}\\left(K_{M,2} + [I_{1}]\\right) = V_{\\max,2}[I_{1}]\n$$\n$$\n\\Longrightarrow \\quad v_{1}K_{M,2} = [I_{1}]\\left(V_{\\max,2} - v_{1}\\right)\n\\quad \\Longrightarrow \\quad\n[I_{1}] = \\frac{v_{1}K_{M,2}}{V_{\\max,2} - v_{1}}.\n$$\n\nThe problem states that $E_{2}$ has an exceptionally low $K_{M,2}$ and a very high $k_{cat,2}$, implying a large $V_{\\max,2}$. For a given upstream supply rate $v_{1}$ (set by $E_{1}$ and $[S]$) that is moderate compared to $V_{\\max,2}$, we have $V_{\\max,2} \\gg v_{1}$, so\n$$\n[I_{1}] \\approx \\frac{v_{1}K_{M,2}}{V_{\\max,2}}.\n$$\nSince $K_{M,2}$ is very small and $V_{\\max,2}$ is very large, the product $\\frac{K_{M,2}}{V_{\\max,2}}$ is small, and thus $[I_{1}]$ is maintained at a very low level. Equivalently, note that\n$$\n\\frac{[I_{1}]}{K_{M,2}} = \\frac{v_{1}}{V_{\\max,2} - v_{1}} \\approx \\frac{v_{1}}{V_{\\max,2}} \\ll 1,\n$$\nso $[I_{1}] \\ll K_{M,2}$ and is therefore far below either $K_{M,2}$ or $K_{M,1}$. The kinetic properties of $E_{2}$ enable rapid consumption of $I_{1}$, preventing its accumulation.\n\nThe downstream enzyme $E_{3}$ having moderate efficiency limits the overall flux $v$ if it is the slowest step, which would further reduce $v_{1}$ and make $[I_{1}]$ even smaller, not larger. There is no mechanism here to cause sustained oscillations in $[I_{1}]$ in a simple linear pathway without feedback.\n\nTherefore, the intracellular concentration of $I_{1}$ will be maintained at a very low level.\n\nThe correct option is A.", "answer": "$$\\boxed{A}$$", "id": "2057431"}, {"introduction": "Once a pathway has been designed, the next challenge is to optimize its performance by fine-tuning the expression levels of its constituent enzymes. This often involves exploring a vast number of genetic combinations, creating a significant experimental challenge. The following exercise [@problem_id:2057449] illustrates the combinatorial complexity of pathway optimization and underscores the value of using hypothesis-driven strategies to narrow down the experimental search space, making the optimization process more manageable and efficient.", "problem": "A synthetic biology team is engineering *Escherichia coli* to produce limonene, a valuable fragrance and biofuel precursor. The synthetic pathway requires the co-expression of four different enzymes: E1, E2, E3, and E4. To optimize the production of limonene, the team needs to tune the expression level of each enzyme individually.\n\nFor each of the four enzymes, the team plans to construct a genetic expression cassette. Each cassette's expression level is determined by the choice of a promoter and a Ribosome Binding Site (RBS). The team has created a library of genetic parts consisting of:\n- A set of 4 distinct promoters of varying strengths.\n- A set of 3 distinct Ribosome Binding Sites (RBSs) of varying translational efficiencies.\n\nFirst, consider an exhaustive optimization strategy (Strategy A) where every possible combination of promoter and RBS is tested for each of the four enzymes.\n\nSecond, a lead scientist proposes a more focused, hypothesis-driven approach (Strategy B). Based on preliminary metabolic flux models, they hypothesize that enzymes E1 and E4 are the primary rate-limiting steps and require maximal expression, while enzymes E2 and E3 require broader tuning to balance the pathway. Therefore, under Strategy B:\n- For enzymes E1 and E4, only the 2 strongest promoters and the single most efficient RBS from the libraries will be tested.\n- For enzymes E2 and E3, the full libraries of all 4 promoters and all 3 RBSs will be tested.\n\nCalculate the total number of unique pathway variants that need to be constructed and tested for Strategy A and Strategy B, respectively. Present your answer as two integers corresponding to Strategy A and Strategy B.", "solution": "Let the number of promoters be $P=4$ and the number of RBSs be $R=3$. For a single enzyme cassette using the full libraries, the number of promoter-RBS combinations is given by the multiplication principle:\n$$\nP \\times R = 4 \\times 3 = 12.\n$$\n\nStrategy A: All four enzymes E1, E2, E3, and E4 each have $12$ choices, independently. By the multiplication principle, the total number of pathway variants is\n$$\n12^{4} = 20736.\n$$\n\nStrategy B: For E1 and E4, only $2$ promoters and $1$ RBS are used, giving $2 \\times 1 = 2$ options each. For E2 and E3, the full libraries are used, giving $4 \\times 3 = 12$ options each. By the multiplication principle, the total number of pathway variants is\n$$\n2 \\times 12 \\times 12 \\times 2 = (2 \\times 2) \\times (12 \\times 12) = 4 \\times 144 = 576.\n$$", "answer": "$$\\boxed{\\begin{pmatrix} 20736 & 576 \\end{pmatrix}}$$", "id": "2057449"}]}